Merck (NYSE:MRK) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for ...
The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback